5 completed, 4 terminated. 9 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Terminated 4 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow pharmaand GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes Rucaparib - Solid Tumor | Phase 2 | Terminated | pharmaand GmbH | 83 | 2020-01-16 | 2023-10-02 |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) Rucaparib, Nivolumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Terminated | pharmaand GmbH | 1 | 2019-08-23 | 2023-06-12 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) Rucaparib, Lucitanib, Sacituzumab govitecan - Ovarian Cancer, Triple-negative Breast Cancer | Phase 1 / Phase 2 | Terminated | pharmaand GmbH | 25 | 2019-06-28 | 2024-01-16 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Rucaparib - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | pharmaand GmbH | 97 | 2018-06-01 | 2023-06-09 |
| A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Rucaparib - Metastatic Castration Resistant Prostate Cancer | Phase 2 | Completed | pharmaand GmbH | 277 | 2017-02-15 | 2023-06-09 |
| Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets - Multiple Myeloma | Phase 2 | Completed | pharmaand GmbH | 248 | 2016-04-27 | 2024-07-12 |
| A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Rucaparib - Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | pharmaand GmbH | 19 | 2014-04-01 | 2023-06-13 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Oral rucaparib - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 | Completed | pharmaand GmbH | 491 | 2013-10-30 | 2023-06-12 |
| A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) Rucaparib - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Completed | pharmaand GmbH | 136 | 2011-11-01 | 2023-06-09 |
Fallopian Tube Neoplasms (4) · Ovarian Neoplasms (4) · Recurrence (3) · Carcinoma, Ovarian Epithelial (2) · Carcinoma, Transitional Cell (2) · Pancreatic Neoplasms (2) · Urinary Bladder Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Endometrioid (1) · Carcinosarcoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Leiomyosarcoma (1)
rucaparib (8) · Bortezomib (1) · Calcium Dobesilate (1) · Dexamethasone (1) · E-3810 (1) · Nivolumab (1) · Panobinostat (1) · sacituzumab govitecan (1)
United States (9) · Spain (5) · Canada (4) · France (4) · United Kingdom (4) · Australia (3) · Germany (3) · Israel (3) · Italy (3) · Belgium (2) · Brazil (1) · Czechia (1) · Denmark (1) · Greece (1) · Hungary (1)
Heidi Giordano (1) · Kathleen N Moore, MD (1) · Kim Reiss-Binder, MD (1)
PMID 35397664, PMID 31685558, PMID 27908594, PMID 29799676, PMID 32203306, PMID 33301738, PMID 33941784, PMID 34030643, PMID 35170751, PMID 36482193, PMID 36898948, PMID 37277275, PMID 40632975
2015 (1), 2016 (1), 2017 (1), 2018 (1)